TREM2 and Alzheimer disease: The phagocytic function of microglial TREM2 in the early middle pathological stage (2–6 months old mice) exacerbated AD pathology by inducing synaptic loss, while its expression in advanced stages (6–10 months) prevented amyloidosis by limiting amyloid deposition.